Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Nasdaq100 ETF (QQQ) Price & Performance

Abeona Therapeutics IncTrade
Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Nasdaq100 ETF — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Nasdaq100 ETF trades at $725.12. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.

ABEOQQQ
Market Cap
$421.19M
Sector
Health
52-Week High
$7.45$746.16
52-Week Low
$4.17$558.34
Enterprise Value
$276.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Nasdaq100 ETF

QQQ trades at $725.07, up 0.59% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro increasing its position by 2,685.7%. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend momentum. The Nasdaq-100 tracker benefits from tech sector strength and AI-driven market leadership.

QQQ's outlook remains positive given tech sector momentum and institutional accumulation. Key risks include concentration in mega-cap tech stocks and potential volatility from Fed policy shifts. The ETF's long-term performance record and current technical setup support continued upside potential, though investors should monitor overbought conditions and sector rotation risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on QQQ